The problem doesn't end there. Once these drugs' exclusive rights expire and "generic brand" prescriptions are allowed to compete, most insured patients will still prefer the "name brand" as they are only charged co-pay. Some insurance providers may place restrictions on which drugs are eligible for treatment but this is not the case with traditional U.S. sponsored Medicare/Medicaid (patients are free to choose betwe…
So, patients pay (a bit), so they avoid unnecessary treatment. But they don't have to pay to much. And if the drug companies try to play funny-buggers, they get shut out.
Also, the subsidy process is completely hands-off (it's run by an untouchable board of experts), so while it's a little inefficient (untouchable experts are always inefficient) it's incorruptible.